References
Steinberg GD, Carter BS, Beaty TH. Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337–47.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.
Trojan L, Kiknavelidze K, Knoll T, Alken P, Michel MS. Prostate cancer therapy: standard management, new options and experimental approaches. Anticancer Res. 2005;25:551–61.
Kucuk O. Chemoprevention of prostate cancer. Cancer Metastasis Rev. 2002;21:111–24.
Gallagher RP, Fleshner N. Prostate cancer: 3. Individual risk factors. CMAJ. 1998;159:807–13.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.
Jemal A, Siegel, Ward E, Murray T, Xu J. and Thun M J. Cancer statistics CA. Cancer. J. Clin. 2007;57: 43–66.
Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc. 2007;82:243–9.
Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822–6.
Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Death receptor-induced cell death in prostate cancer. J Cell Biochem. 2004;91:70–99.
Thornberry NA. Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312–6.
Vela-Navarrete R, Escribano-Burgos M, Farré AL, García-Cardoso J, Manzarbeitia F, Carrasco C. Serenoa repens treatment modifies Bax/Bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. Urology. 2005;173:507–10.
Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008;13:3046–82.
Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Up-regulation of poly(ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer. 2010;8:812–21.
Cussenot O, Berthon P, Berger R, Mowszowicz I, Faille A. Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J Urol. 1991;146:881–6.
Berthon P, Cussenot O, Hopwood L, Leduc A, Maitland N. Functional expression of sv40 in normal human prostatic epithelial and fibroblastic cells—differentiation pattern of nontumorigenic cell-lines. Int J Oncol. 1995;6:333–43.
Marcelli M, Cunningham GR, Haidacher SJ., Padayatty SJ, Sturgis L, Kagan C, Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res. 1998;58:76–83.
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979;17:16–23.
Calogero AE, Soma PF, Giuffrida MC, Giuffrida D, La Vignera S, Romano C, Castiglione R, Bosco P, Salemi M. PARP1 and CASP3 gene expression in a patient with multiple head and neck squamous cell carcinoma and Parkinson disease. Hum Cell. 2013;26:44–6.
Ha HC, Snyder SH. Poly (ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA. 1999;96:13978–82.
Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J. Notch/HES1-mediated PARP1 activation: a cell-type specific mechanism for tumor suppression. Blood. 2011;117: 2891-2900;85: 669–79.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salemi, M., Condorelli, R.A., La Vignera, S. et al. PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines. Human Cell 27, 172–175 (2014). https://doi.org/10.1007/s13577-013-0076-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13577-013-0076-5